UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 5, 2020
PARALLAX HEALTH SCIENCES, INC.
(Exact name of Company as specified in its charter)
|
Nevada |
000-52534 |
46-4733512 |
|
(State or other jurisdiction |
(Commission File Number) |
(IRS Employer |
|
of Incorporation) |
|
Identification Number) |
|
|
1327 Ocean Avenue, Suite B Santa Monica, CA 90401 (Address of principal executive offices)
310-899-4442 (Registrant’s Telephone Number) |
|
|
Copy of all Communications to: Peter V. Hogan Buchalter 1000 Wilshire Boulevard, Suite 1500 Los Angeles, CA 90017 (213) 891-0700
|
||
As used in this current report and unless otherwise indicated, the terms "we", "us", "our", “Company”, and “Parallax” mean Parallax Health Sciences, Inc., a Nevada corporation, and its subsidiaries, unless otherwise indicated.
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
The disclosures set forth in Item 3.02 are incorporated into this Item 1.01 by reference.
ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES
On or about March 5, 2020, in connection with a $5,000,000 maximum offering of the Company’s Series B1 Convertible Preferred Stock (the “Series B1 Stock”), the Company received subscriptions from accredited investors (the “Subscriptions”) for the purchase of 36 shares of Series B1 Stock at a price of $10,000 per share, net of an original issue discount of 15%, or $8,500 per share, for proceeds in the amount of $306,000.
The Series B1 Stock is redeemable at 120% of face value and unpaid dividends; is convertible into common stock at a conversion rate of $0.15; carries an annual dividend of 10%; and matures in two (2) years, at which time the Series B1 Stock will automatically convert into common stock. In addition, the Subscription includes 50% warrant coverage at an exercise price of $0.25 per share for a period of three (3) years.
The foregoing disclosure and summary of the Series B1 Stock designation set forth in this Section 3.02 does not purport to be complete, and is qualified in its entirety by reference to the Certificate of Designation for Series B1 Preferred Stock filed as Exhibit 3.1 to the Current Report on Form 8-K February 13, 2020, and incorporated by reference herein.
The issuance of the Series B1 Stock and Warrants were made in reliance on exemption from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended, on the basis that the Registrant had a pre-existing relationship with the investor and there was no public offering.
ITEM 8.01OTHER EVENTS
On March 11, 2020, Parallax Health Sciences, Inc. published the press release which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
|
Exhibit Number |
Description of Exhibit |
Filing Reference |
|
Filed with the SEC on February 13, 2020 as part of the Company's Current Report on Form 8-K. |
||
|
Filed herewith |
* Confidential disclosure schedules omitted. The Registrant undertakes to furnish copies of any omitted schedules to the SEC upon request.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
PARALLAX HEALTH SCIENCES, INC. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dated: March 11, 2020 |
/s/ Paul R. Arena |
|
|
|
|
Paul R. Arena |
|
|
|
|
Chief Executive Officer |
|
|
|
|
|
|
